Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 1/20 | 0.40 |
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
| ▸ | ITGB1 | P05556 | 12/20 | 0.40 |
| ▸ | ITGA4 | P13612 | 12/20 | 0.40 |
| ▸ | ITGB7 | P26010 | 11/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.40 |
| ▸ | F10 | P00742 | 1/20 | 0.39 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.37 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7206530 | 0.89 | TSHR (0.45) | MMP1MMP13MEN1KMT2A | |
| SCHEMBL7204213 | 0.88 | MMP13 (0.52) | MMP1MMP13DPP4DPP7KDM2B | |
| SCHEMBL7201014 | 0.87 | SMN1; SMN2 (0.41) | MMP1MMP13MEN1KMT2A | |
| SCHEMBL7292292 | 0.86 | AKR1C3 (0.45) | MMP1MMP13DPP4DPP7F10 | |
| SCHEMBL7205673 | 0.86 | MMP1 (0.39) | MMP1MMP13DPP4DPP7F10 | |
| SCHEMBL7205455 | 0.86 | MMP9 (0.44) | MMP1MMP13 | |
| SCHEMBL7206504 | 0.84 | MMP1 (0.47) | MMP1MMP13F10 | |
| SCHEMBL7201767 | 0.83 | NAAA (0.44) | MMP13F10PAX8MEN1KMT2A | |
| SCHEMBL7201540 | 0.83 | ADAMTS4 (0.39) | MMP1MMP13DPP4 | |
| SCHEMBL7300738 | 0.83 | MMP13 (0.48) | MMP1MMP13MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6608104-B2 | Antiarthritic agents; anticancer agents | PFIZER INC | 2003-08-19 | — | — | US | disclosed |
| US-20020019534-A1 | Gem substituted hydroxamic acids | PFIZER INC. | 2002-02-14 | — | — | US | disclosed |
| EP-1138680-A1 | Gem substituted sulfonyl hydroxamic acids as MMP inhibitors | Pfizer Products Inc. (US) | 2001-10-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019534-A1 | Gem substituted hydroxamic acids | MMP14, TOP2A, ADAMTS1 | MMP1 8/4885MMP13 4/4885ITGB1 2459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.